Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors

ConclusionsPrexasertib in combination with PD-L1 blockade was tolerable and demonstrated preliminary activity inCCNE1-amplified HGSOC with evidence of cytotoxic T-cell activation in patient blood samples.Trial registrationClinicalTrials.gov identifier: NCT03495323. Registered April 12, 2018.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research